

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant J. Vernon Knight <i>et al.</i>	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
AS	A1	5,049,388	11/17/91	Knight <i>et al.</i>	424	450	07/21/89
	A2	5,422,344	06/06/95	Priel <i>et al.</i>	514	50	05/08/90
	A3	5,552,156	11/03/96	Burke	424	450	03/22/95
	A4	5,736,156	04/07/98	Burke	424	450	04/12/96
	A5	5,958,378	11/28/99	Waldrep <i>et al.</i>	424	45	10/16/96
	A6	6,090,407	07/18/00	Knight <i>et al.</i>	424	450	11/23/97
↓	A7	6,346,233	02/12/02	Knight <i>et al.</i>	424	45	07/17/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
AS	B1	DB 4430593C2	08/20/94	Germany	Abstract
	B2	WO 9318751	03/23/93	WIPO	English
	B3	WO 9426253	05/16/94	WIPO	English
	B4	WO 9605821	08/18/95	WIPO	Abstract
↓	B5	WO 9619199	12/20/95	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AS	C1	"Chiron submits new drug application for pulmini; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection," www.drugs.com/nda/pulmini_041014.html 9/14/06
AS	C2	Abang <i>et al.</i> , "The clinical pharmacology of topoisomerase I inhibitors," <i>Sem Hematol</i> , 35:13-21, 1998.

25695214.1

EXAMINER: /Aradhana Sasan/	DATE CONSIDERED: 01/17/2007
----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant J. Vernon Knight <i>et al.</i>	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Inft.	Ref. Des.	Citation
AS	C3	Ahmed <i>et al.</i> , "Influence of route of administration on [3h]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies," <i>Cancer Chemother Pharmacol.</i> , 39:122-130, 1996.
	C4	Anderson, "Delivery systems for immunomodulatory proteins and peptides," <i>BioDrugs</i> , 7:51-65, 1997.
	C5	Burckart <i>et al.</i> , "Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients," <i>Pharmaceutical Research</i> , 20:252-256, 2003.
	C6	Chourpa <i>et al.</i> , "Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA," <i>Biochem.</i> , 37:7284-7291, 1998.
	C7	Fresta <i>et al.</i> , "Evaluation and optimization of liposomes as delivery device for methotrexate," <i>Pharmazie</i> , 47:926-929, 1992.
	C8	Garcia-Carbonero <i>et al.</i> , "Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins," <i>Clin. Cancer Res.</i> , 8:641-661, 2002.
	C9	Giovanella <i>et al.</i> , "Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin," <i>Cancer Res.</i> , 51:3052-3055, 1991.
	C10	Hallman <i>et al.</i> , "Inositol supplementation in premature infants with respiratory distress syndrome," <i>N. Eng. J. Med.</i> , 326:1233-1239, 1992.
	C11	Hausheer <i>et al.</i> , "Karenitecins: a novel, potent class of oral highly lipophilic topo I inhibitors," <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , 38:A1526, 1997.
	C12	Hertzberg <i>et al.</i> , "Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity," <i>J. Medic. Chem.</i> , 32:715-720, 1989.
	C13	Hochster <i>et al.</i> , "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen," <i>J. Clin. Oncol.</i> , 12:553-559, 1994.
	C14	Iacono <i>et al.</i> , "Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans," <i>Eur. Respir. J.</i> , 23:384-390, 2004.
	C15	Kim <i>et al.</i> , "Pharmacodynamics of insulin in polyethylene glycol-coated liposomes," <i>Int. J. Pharm.</i> , 180:75-81, 1999.
↓	C16	Knight <i>et al.</i> , "New approaches in aerosol drug delivery for the treatment of asthma," in <i>Allergy and Allergic Diseases</i> , Kay (ed), Blackwell Publications, Oxford, England, 1:730-741. (date unknown)

25695214.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)